Cutting edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity

William E. Matchett; Vineet Joag; J. Michael Stolley; Frances K. Shepherd; Clare F. Quarnstrom; Clayton K. Mickelson; Sathi Wijeyesinghe; Andrew G. Soerens; Samuel Becker; Joshua M. Thiede; Eyob Weyu; Stephen D. O'Flanagan; Jennifer A. Walter; Michelle N. Vu; Vineet D. Menachery; Tyler D. Bold; Vaiva Vezys; Marc K. Jenkins; Ryan A. Langlois; David Masopust

doi:10.4049/jimmunol.2100421

Cutting edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity

William E. Matchett, Vineet Joag, J. Michael Stolley, Frances K. Shepherd, Clare F. Quarnstrom, Clayton K. Mickelson, Sathi Wijeyesinghe, Andrew G. Soerens, Samuel Becker, Joshua M. Thiede, Eyob Weyu, Stephen D. O'Flanagan, Jennifer A. Walter, Michelle N. Vu, Vineet D. Menachery, Tyler D. Bold, Vaiva Vezys, Marc K. Jenkins, Ryan A. Langlois, David Masopust

Microbiology And Immunology

Research output: Contribution to journal › Article › peer-review

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and K18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral Ags in SARS-CoV-2 vaccines, even if they are not a target of neutralizing Abs, to broaden epitope coverage and immune effector mechanisms.

Original language	English (US)
Pages (from-to)	376-379
Number of pages	4
Journal	Journal of Immunology
Volume	207
Issue number	2
DOIs	https://doi.org/10.4049/jimmunol.2100421
State	Published - Jul 15 2021

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.4049/jimmunol.2100421

Cite this

Matchett, W. E., Joag, V., Stolley, J. M., Shepherd, F. K., Quarnstrom, C. F., Mickelson, C. K., Wijeyesinghe, S., Soerens, A. G., Becker, S., Thiede, J. M., Weyu, E., O'Flanagan, S. D., Walter, J. A., Vu, M. N., Menachery, V. D., Bold, T. D., Vezys, V., Jenkins, M. K., Langlois, R. A., & Masopust, D. (2021). Cutting edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. Journal of Immunology, 207(2), 376-379. https://doi.org/10.4049/jimmunol.2100421

Matchett, WE, Joag, V, Stolley, JM, Shepherd, FK, Quarnstrom, CF, Mickelson, CK, Wijeyesinghe, S, Soerens, AG, Becker, S, Thiede, JM, Weyu, E, O'Flanagan, SD, Walter, JA, Vu, MN, Menachery, VD, Bold, TD, Vezys, V, Jenkins, MK, Langlois, RA & Masopust, D 2021, 'Cutting edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity', Journal of Immunology, vol. 207, no. 2, pp. 376-379. https://doi.org/10.4049/jimmunol.2100421

@article{7e07971407524fac87a3fd7eb4312e7b,

title = "Cutting edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity",

abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and K18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral Ags in SARS-CoV-2 vaccines, even if they are not a target of neutralizing Abs, to broaden epitope coverage and immune effector mechanisms.",

author = "Matchett, {William E.} and Vineet Joag and Stolley, {J. Michael} and Shepherd, {Frances K.} and Quarnstrom, {Clare F.} and Mickelson, {Clayton K.} and Sathi Wijeyesinghe and Soerens, {Andrew G.} and Samuel Becker and Thiede, {Joshua M.} and Eyob Weyu and O'Flanagan, {Stephen D.} and Walter, {Jennifer A.} and Vu, {Michelle N.} and Menachery, {Vineet D.} and Bold, {Tyler D.} and Vaiva Vezys and Jenkins, {Marc K.} and Langlois, {Ryan A.} and David Masopust",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 by The American Association of Immunologists, Inc.",

year = "2021",

month = jul,

day = "15",

doi = "10.4049/jimmunol.2100421",

language = "English (US)",

volume = "207",

pages = "376--379",

journal = "Journal of Immunology",

issn = "0022-1767",

publisher = "American Association of Immunologists",

number = "2",

}

TY - JOUR

T1 - Cutting edge

T2 - Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity

AU - Matchett, William E.

AU - Joag, Vineet

AU - Stolley, J. Michael

AU - Shepherd, Frances K.

AU - Quarnstrom, Clare F.

AU - Mickelson, Clayton K.

AU - Wijeyesinghe, Sathi

AU - Soerens, Andrew G.

AU - Becker, Samuel

AU - Thiede, Joshua M.

AU - Weyu, Eyob

AU - O'Flanagan, Stephen D.

AU - Walter, Jennifer A.

AU - Vu, Michelle N.

AU - Menachery, Vineet D.

AU - Bold, Tyler D.

AU - Vezys, Vaiva

AU - Jenkins, Marc K.

AU - Langlois, Ryan A.

AU - Masopust, David

PY - 2021/7/15

Y1 - 2021/7/15

N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and K18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral Ags in SARS-CoV-2 vaccines, even if they are not a target of neutralizing Abs, to broaden epitope coverage and immune effector mechanisms.

AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with a human adenovirus type 5 vector expressing the SARS-CoV-2 nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and K18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral Ags in SARS-CoV-2 vaccines, even if they are not a target of neutralizing Abs, to broaden epitope coverage and immune effector mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=85111142331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111142331&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.2100421

DO - 10.4049/jimmunol.2100421

M3 - Article

C2 - 34193597

AN - SCOPUS:85111142331

SN - 0022-1767

VL - 207

SP - 376

EP - 379

JO - Journal of Immunology

JF - Journal of Immunology

IS - 2

ER -

Cutting edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this